Reports related to this article:
Project(s): View 6 related projects in PECWeb
Plant(s): View 6 related plants in PECWeb
Released September 23, 2025 | SUGAR LAND
en
Researched by Industrial Info Resources (Sugar Land, Texas)--As the White House aims to boost domestic manufacturing capacity of pharmaceuticals, industry giants are announcing capital investment in the U.S.
Eli Lilly and Company (Indianapolis, Indiana) recently said it plans to build a $5 billion manufacturing facility in Virginia--the first of four planned manufacturing sites in the U.S.--and GSK plc (London, United Kingdom) announced plans to invest $30 billion in U.S. research and development (R&D) and manufacturing over the next five years.
In a September 16 press release, Eli Lilly said the new Virginia site will be the company's "first dedicated, fully integrated active pharmaceutical ingredient (API) and drug product facility for Lilly's emerging bioconjugate platform and monoclonal antibody portfolio." Treatments would primarily be used to treat cancer but "are being explored for autoimmune diseases and other conditions."
The company expects the project to be completed within the next five years, although Industrial Info is currently tracking the project with a low probability of kicking off in June 2026. Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical-Biotech Project Database can click here for the project report.
"Virginia's new multibillion-dollar drug manufacturing plant is the latest in a long line of investments spurred by President Trump's agenda," White House spokeswoman Victoria LaCivita told the Washington Reporter.
Industrial Info is tracking more than $28 billion worth of capital projects from Eli Lilly across the U.S., which includes other high-dollar manufacturing plants. Subscribers can click here for a full list of projects.
This includes projects underway aimed at building out a manufacturing campus within the LEAP (Limitless Exploration Advanced Pace) Innovation District in Lebanon, Indiana, about 30 miles from Lilly's headquarters in Indianapolis.
More than $7 billion worth of investment is attributed to the project entailing the construction of two grassroot peptide-manufacturing buildings as well as work in order to house new API manufacturing for glucose-related drugs. Production is expected to begin in 2028 and scale up through the end of the year.
Also underway at the site are two projects set to wrap up by year-end 2027: a $500 million grassroot facility, which will manufacture APIs and cell and gene therapies, and a $600 million expansion to expand manufacturing capacity for brand name and generic APIs. Subscribers can click here for the related project reports.
Construction of Eli Lilly's planned $4.5 billion medicine foundry in the LEAP district is expected to begin in mid-2026. Seven buildings totaling 1.2 billion square feet would integrate the entire drug-making process--housing drug development, research activities and clinical-scale production for API molecular therapies, molecules and nucleic acid therapies. Subscribers can click here for the project report.
Another major drugmaker, GSK, also recently announced major planned U.S. investment: $30 billion for R&D and manufacturing over the next five years--which includes roughly $1 billion for a new manufacturing plant.
According to a company press release, the investment entails "construction of an additional new biologics flex factory at Upper Merion, Pennsylvania to deliver potential best-in-class new medicines for respiratory disease (COPD, asthma) and cancer (haematological, gynaecological, lung and other solid tumours)." The company said it expects construction will begin in 2026, although Industrial Info is currently tracking the project with a low probability of moving forward as planned.
Subscribers can click here to read the project report.
GSK said the announcement means it has pledged approximately $2 billion worth of new investments in U.S. manufacturing over the last 12 months. The company pointed specifically to an $800 million addition underway at its site in Marietta, Pennsylvania. The multi-purpose facility will be capable of manufacturing sterile liquid vaccines and medicines, as well as drug substances, and also house a state-of-the-art R&D pilot plant to manufacture medicines for clinical trials. This expansion will double the size and capacity of the Marietta site. Subscribers can click here to read the project report.
"The vast majority of our products going into the U.S. are manufactured in the U.S.," said GSK Chief Executive Emma Walmsley in a recent interview with The Wall Street Journal. "This of course adds to it, and it's about the new pipeline that's going through."
According to analysis by the WSJ, more than a dozen drugmakers have pledged to spend more than a combined $350 billion by the end of the decade on manufacturing, R&D and other efforts in the U.S.
This includes $55 billion over four years from Johnson & Johnson (New Brunswick, New Jersey) and $50 billion by 2030 from AstraZeneca (Cambridge, U.K.). Other companies with commitments include Sanofi (Paris, France) and Roche (Basel, Switzerland).
The investment comes as President Donald Trump aims to move drug production to the U.S.
In May, Trump signed an executive order directing the U.S. Food and Drug Administration "to reduce the amount of time it takes to approve domestic pharmaceutical manufacturing plants by eliminating duplicative and unnecessary requirements, streamlining reviews, and working with domestic manufacturers to provide early support before facilities come online," among other components.
"Estimates suggest that building new manufacturing capacity for pharmaceuticals and critical inputs may take as long as five to ten years ... this order will speed up timelines for building domestic pharmaceutical manufacturing site(s) by reducing regulatory barriers to construction."
Subscribers can click here for a full list of detailed reports for projects mentioned in this article, and click here for a full list of related plant profiles.
Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) platform helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking more than 200,000 current and future projects worth $17.8 trillion (USD).
Eli Lilly and Company (Indianapolis, Indiana) recently said it plans to build a $5 billion manufacturing facility in Virginia--the first of four planned manufacturing sites in the U.S.--and GSK plc (London, United Kingdom) announced plans to invest $30 billion in U.S. research and development (R&D) and manufacturing over the next five years.
In a September 16 press release, Eli Lilly said the new Virginia site will be the company's "first dedicated, fully integrated active pharmaceutical ingredient (API) and drug product facility for Lilly's emerging bioconjugate platform and monoclonal antibody portfolio." Treatments would primarily be used to treat cancer but "are being explored for autoimmune diseases and other conditions."
The company expects the project to be completed within the next five years, although Industrial Info is currently tracking the project with a low probability of kicking off in June 2026. Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical-Biotech Project Database can click here for the project report.
"Virginia's new multibillion-dollar drug manufacturing plant is the latest in a long line of investments spurred by President Trump's agenda," White House spokeswoman Victoria LaCivita told the Washington Reporter.
Industrial Info is tracking more than $28 billion worth of capital projects from Eli Lilly across the U.S., which includes other high-dollar manufacturing plants. Subscribers can click here for a full list of projects.
This includes projects underway aimed at building out a manufacturing campus within the LEAP (Limitless Exploration Advanced Pace) Innovation District in Lebanon, Indiana, about 30 miles from Lilly's headquarters in Indianapolis.
More than $7 billion worth of investment is attributed to the project entailing the construction of two grassroot peptide-manufacturing buildings as well as work in order to house new API manufacturing for glucose-related drugs. Production is expected to begin in 2028 and scale up through the end of the year.
Also underway at the site are two projects set to wrap up by year-end 2027: a $500 million grassroot facility, which will manufacture APIs and cell and gene therapies, and a $600 million expansion to expand manufacturing capacity for brand name and generic APIs. Subscribers can click here for the related project reports.
Construction of Eli Lilly's planned $4.5 billion medicine foundry in the LEAP district is expected to begin in mid-2026. Seven buildings totaling 1.2 billion square feet would integrate the entire drug-making process--housing drug development, research activities and clinical-scale production for API molecular therapies, molecules and nucleic acid therapies. Subscribers can click here for the project report.
Another major drugmaker, GSK, also recently announced major planned U.S. investment: $30 billion for R&D and manufacturing over the next five years--which includes roughly $1 billion for a new manufacturing plant.
According to a company press release, the investment entails "construction of an additional new biologics flex factory at Upper Merion, Pennsylvania to deliver potential best-in-class new medicines for respiratory disease (COPD, asthma) and cancer (haematological, gynaecological, lung and other solid tumours)." The company said it expects construction will begin in 2026, although Industrial Info is currently tracking the project with a low probability of moving forward as planned.
Subscribers can click here to read the project report.
GSK said the announcement means it has pledged approximately $2 billion worth of new investments in U.S. manufacturing over the last 12 months. The company pointed specifically to an $800 million addition underway at its site in Marietta, Pennsylvania. The multi-purpose facility will be capable of manufacturing sterile liquid vaccines and medicines, as well as drug substances, and also house a state-of-the-art R&D pilot plant to manufacture medicines for clinical trials. This expansion will double the size and capacity of the Marietta site. Subscribers can click here to read the project report.
"The vast majority of our products going into the U.S. are manufactured in the U.S.," said GSK Chief Executive Emma Walmsley in a recent interview with The Wall Street Journal. "This of course adds to it, and it's about the new pipeline that's going through."
According to analysis by the WSJ, more than a dozen drugmakers have pledged to spend more than a combined $350 billion by the end of the decade on manufacturing, R&D and other efforts in the U.S.
This includes $55 billion over four years from Johnson & Johnson (New Brunswick, New Jersey) and $50 billion by 2030 from AstraZeneca (Cambridge, U.K.). Other companies with commitments include Sanofi (Paris, France) and Roche (Basel, Switzerland).
The investment comes as President Donald Trump aims to move drug production to the U.S.
In May, Trump signed an executive order directing the U.S. Food and Drug Administration "to reduce the amount of time it takes to approve domestic pharmaceutical manufacturing plants by eliminating duplicative and unnecessary requirements, streamlining reviews, and working with domestic manufacturers to provide early support before facilities come online," among other components.
"Estimates suggest that building new manufacturing capacity for pharmaceuticals and critical inputs may take as long as five to ten years ... this order will speed up timelines for building domestic pharmaceutical manufacturing site(s) by reducing regulatory barriers to construction."
Subscribers can click here for a full list of detailed reports for projects mentioned in this article, and click here for a full list of related plant profiles.
Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) platform helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking more than 200,000 current and future projects worth $17.8 trillion (USD).
